USD
$0.00
(0.00%
)At Close (As of Sep 5, 2025)
$64.58M
Market Cap
-
P/E Ratio
-1.62
EPS
$3.89
52 Week High
$1.10
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$53M |
Selling General And Administrative | $9.4M |
Research And Development | $45M |
Operating Expenses | $53M |
Investment Income Net | - |
Net Interest Income | -$1.9M |
Interest Income | - |
Interest Expense | $1.9M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | -$52M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$52M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | - |
Net Income | -$52M |
Field | Value (USD) |
---|---|
Total Assets | $71M |
Total Current Assets | $64M |
Cash And Cash Equivalents At Carrying Value | $61M |
Cash And Short Term Investments | $61M |
Inventory | - |
Current Net Receivables | $1.2M |
Total Non Current Assets | $7.2M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $40K |
Intangible Assets Excluding Goodwill | $40K |
Goodwill | - |
Investments | - |
Long Term Investments | $4.2M |
Short Term Investments | $7K |
Other Current Assets | $2M |
Other Non Current Assets | - |
Total Liabilities | $46M |
Total Current Liabilities | $45M |
Current Accounts Payable | $10M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $27M |
Total Non Current Liabilities | $425K |
Capital Lease Obligations | $896K |
Long Term Debt | - |
Current Long Term Debt | $26M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $27M |
Other Current Liabilities | $3.3M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $25M |
Treasury Stock | - |
Retained Earnings | -$429M |
Common Stock | $11K |
Common Stock Shares Outstanding | $111M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$52M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.9M |
Capital Expenditures | $170K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $28M |
Cashflow From Financing | -$6.6M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $0 |
Dividend Payout Common Stock | $0 |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$52M |
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$53M |
Selling General And Administrative | $9.4M |
Research And Development | $45M |
Operating Expenses | $53M |
Investment Income Net | - |
Net Interest Income | -$1.9M |
Interest Income | - |
Interest Expense | $1.9M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | -$52M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$52M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | - |
Net Income | -$52M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.